<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5425-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACARIZAX 12SQ-HDM ORALLY LYOPHILISATE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DERMATOPHAGOIDES FARINAE EXTRACT, DERMATOPHAGOIDES PTERONYSSINUS EXTRACT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Sublingual use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral lyophilisate
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        323.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Catalent UK Swindon Zydis Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Catalent UK Swindon Zydis Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALK-Abello A/S
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V01AA03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ACARIZAX 12 SQ-HDM oral lyophilisate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and 
Dermatophagoides farinae 12 SQ-HDM* per oral lyophilisate 
For a full list of excipients, see section 6.1 
* [SQ-HDM is the dose unit for ACARIZAX. SQ is a method for standardisation on biological potency, major allergen content and complexity of the allergen extract. HDM is an abbreviation for house dust mite.] 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral lyophilisate
White to off-white freeze-dried debossed oral lyophilisate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX is indicated in adult patients from the age of 18 through 65 years diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:</p><p style="margin-left:36.05pt; margin-right:10.7pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication</p><p style="margin-left:36.05pt; margin-right:10.7pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis.&nbsp; Patients&#39; asthma status should be carefully evaluated before the initiation of treatment (see section 4.3).&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX is indicated in adolescents from the age of 12 through 17 years diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p style="margin-left:-.2pt; margin-right:10.7pt">The recommended dose for adults and adolescents (12-17 years) is one oral lyophilisate (12 SQ-HDM) daily. Onset of the clinical effect is to be expected 8-14 weeks after initiation. International treatment guidelines refer to a treatment period of 3 years for allergy immunotherapy to achieve disease modification. Efficacy data is available for 18 months of treatment with ACARIZAX in adults; no data is available for 3 years of treatment (see section 5.1). If no improvement is observed during the first year of treatment with ACARIZAX, there is no indication for continuing treatment.&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Method of administration</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX treatment should be initiated by physicians with experience in treatment of allergic diseases.&nbsp; It is recommended that the first oral lyophilisate is taken under medical supervision and that the patient is monitored for at least half an hour, to enable discussion and possible treatment of any immediate side effects.&nbsp; ACARIZAX is an oral lyophilisate. The oral lyophilisate should be taken with dry fingers from the blister unit immediately after opening the blister and placed under the tongue, where it will disperse. Swallowing should be avoided for approximately 1 minute. Food and beverage should not be taken for the following 5 minutes.</p><p style="margin-left:-.2pt; margin-right:10.7pt">If treatment with ACARIZAX is interrupted for a period up to 7 days, treatment can be resumed by the patient. If the treatment is interrupted for more than 7 days it is recommended to contact a physician before resuming the treatment.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Paediatric population</p><p style="margin-left:-.2pt; margin-right:10.7pt">Allergic rhinitis: The posology is the same for adults and adolescents (12-65 years). Clinical experience in treatment of allergic rhinitis with ACARIZAX in children &lt;12 years of age has not been established. ACARIZAX is not intended for treatment of allergic rhinitis in children &lt;12 years of age. Currently available data are described in section 5.1.&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">Allergic asthma: Clinical experience in treatment of allergic asthma with ACARIZAX in children &lt;18 years of age has not been established. ACARIZAX is not intended for treatment of allergic asthma in children &lt;18 years of age.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Elderly population</p><p style="margin-left:-.2pt; margin-right:10.7pt">Clinical experience on immunotherapy with ACARIZAX in adults &gt;65 years of age has not been established. ACARIZAX is not intended for use in adults &gt;65 years of age (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to any of the excipients (for a full list of excipients, see section 6.1).  
Patients with FEV1 < 70% of predicted value (after adequate pharmacological treatment) at initiation of treatment. 
Patients who have experienced a severe asthma exacerbation within the last 3 months. 
In patients with asthma and experiencing an acute respiratory tract infection, initiation of ACARIZAX treatment should be postponed until the infection has resolved. 
Patients with active or poorly controlled autoimmune diseases, immune defects, immunodeficiencies, immunosuppression or malignant neoplastic diseases with current disease relevance. Patients with acute severe oral inflammation or oral wounds (see section 4.4). 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Asthma</p><p style="margin-left:-.2pt; margin-right:10.7pt">Asthma is a known risk factor for severe systemic allergic reactions.</p><p style="margin-left:-.2pt; margin-right:10.7pt">Patients should be advised that ACARIZAX is not intended to treat acute asthma exacerbations. In the event of an acute asthma exacerbation, a short-acting bronchodilator should be used. If patients find short-acting bronchodilator treatment ineffective or they need more inhalations than usual, medical attention must be sought.&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">Patients must be informed of the need to seek medical attention immediately if their asthma deteriorates suddenly.</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX should initially be used as add on therapy and not as a substitute of pre-existing asthma medication. Abrupt discontinuation of asthma controller medication after initiation of ACARIZAX treatment is not recommended. Reductions in asthma controller medication should be performed gradually under the supervision of a physician according to asthma management guidelines.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Severe systemic allergic reactions&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">Treatment should be discontinued and a physician should be contacted immediately<strong><em> </em></strong>in case of severe systemic allergic reactions, severe asthma exacerbation, angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, hypotension or feeling of fullness in the throat. The onset of systemic symptoms may include flushing, pruritus, sense of heat, general discomfort and agitation/anxiety. <strong><em>&nbsp;</em></strong></p><p style="margin-left:-.2pt; margin-right:10.7pt">One option for treating severe systemic allergic reactions is adrenaline. The effects of adrenaline may be potentiated in patients treated with tricyclic antidepressants, mono amino oxidase inhibitors (MAOIs) and/or COMT inhibitors with possible fatal consequences. The effects of adrenaline may be reduced in patients treated with beta-blockers.&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">Patients with cardiac disease may be at increased risk in case of systemic allergic reactions. Clinical experience in treatment with ACARIZAX of patients with cardiac disease is limited.&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">This should be taken into consideration prior to initiating allergy immunotherapy.</p><p style="margin-left:-.2pt; margin-right:10.7pt">Initiation of ACARIZAX in patients who have previously had a systemic allergic reaction to subcutaneous house dust mite immunotherapy should be carefully considered, and measures to treat potential reactions should be available. This is based on post-marketing experience from a corresponding sublingual tablet product for grass pollen immunotherapy which indicates that the risk of a severe allergic reaction may be increased for patients who have previously experienced a systemic allergic reaction to subcutaneous grass pollen immunotherapy.&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p>Oral inflammation</p><p style="margin-left:-.2pt; margin-right:10.7pt">In patients with severe oral inflammation (e.g. oral lichen planus, mouth ulcers or thrush), oral wounds or following oral surgery, including dental extraction, or following tooth loss, initiation of ACARIZAX treatment should be postponed and ongoing treatment should be temporarily interrupted to allow healing of the oral cavity.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Local allergic reactions&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">When treated with ACARIZAX the patient is exposed to the allergen that causes the allergic symptoms. Therefore, local allergic reactions are to be expected during the treatment period. These reactions are usually mild or moderate; however, more severe oropharyngeal reactions may<strong> </strong>occur. If the patient experiences significant local adverse reactions from the treatment, anti-allergic medication (e.g. antihistamines) should be considered.&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Eosinophilic oesophagitis</p><p style="margin-left:-.2pt; margin-right:10.7pt">Cases of eosinophilic oesophagitis have been reported in association with ACARIZAX treatment. In patients with severe or persisting gastro-oesophageal symptoms such as dysphagia or dyspepsia, ACARIZAX should be interrupted and medical evaluation must be sought.&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Autoimmune diseases in remission<strong> </strong></p><p style="margin-left:-.2pt; margin-right:10.7pt">Limited data is available on treatment with allergy immunotherapy in patients with autoimmune diseases in remission. ACARIZAX should therefore be prescribed with caution in these patients.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Food allergy</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX may contain trace amounts of fish protein. Available data have not indicated an increased risk of allergic reactions in patients with fish allergy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">No interaction trials have been conducted in humans and no potential drug interactions have been identified from any source. Concomitant therapy with symptomatic anti-allergic medications may increase the tolerance level of the patient to immunotherapy. This should be considered at discontinuation of such medications.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p style="margin-left:-.2pt; margin-right:10.7pt">There is no data on the clinical experience for the use of ACARIZAX in pregnant women. Animal studies do not indicate increased risk to the foetus. Treatment with ACARIZAX should not be initiated during pregnancy. If pregnancy occurs during treatment, the treatment may continue after evaluation of the general condition (including lung function) of the patient and reactions to previous administration of ACARIZAX. In patients with pre-existing asthma, close supervision during pregnancy is recommended.</p><p style="margin-left:.1pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Lactation</p><p style="margin-left:-.2pt; margin-right:10.7pt">No clinical data are available for the use of ACARIZAX during lactation. No effects on the breastfed infants are anticipated.&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><strong>&nbsp;</strong></p><p>Fertility</p><p style="margin-left:-.2pt; margin-right:10.7pt">There is no clinical data with respect to fertility for the use of ACARIZAX. In a repeat dose toxicity study in mice, no effects were observed in the reproductive organs of both genders.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">Treatment with ACARIZAX has no or negligible influence on the ability to drive or use machines.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p style="margin-left:-.2pt; margin-right:10.7pt">Subjects taking ACARIZAX should primarily expect mild to moderate local allergic reactions to occur within the first few days and subsiding again with continued treatment (1-3 months) (see section 4.4). For the majority of events, the reaction should be expected to start within 5 minutes after intake of ACARIZAX on each day of occurrence and abate after minutes to hours. More severe oropharyngeal allergic reactions may occur (see section 4.4).</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">Isolated cases of severe acute worsening of asthma symptoms have been reported. Patients with known risk factors should not initiate treatment with ACARIZAX (see section 4.3).</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Tabulated list of adverse reactions</p><p style="margin-left:-.2pt; margin-right:10.7pt">The following table of adverse reactions is based on data from placebo-controlled clinical trials investigating ACARIZAX in adult and adolescent patients with house dust mite allergic rhinitis and/or allergic asthma and spontaneous reporting.</p><p style="margin-left:-.2pt; margin-right:10.7pt">Adverse reactions are divided into groups according to the MedDRA convention frequencies: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="0" style="width:504.5pt"><tbody><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>System Organ Class </strong></p></td><td style="border-color:black; height:14.65pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Frequency </strong></p></td><td style="border-color:black; height:14.65pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Adverse Drug Reaction </strong></p></td></tr><tr><td rowspan="3" style="border-color:black; height:14.6pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Infections and infestations</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:14.6pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Very common </em></p></td><td style="height:14.6pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Nasopharyngitis</p></td></tr><tr><td style="height:14.6pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Common </em></p></td><td style="height:14.6pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Bronchitis, pharyngitis, rhinitis, sinusitis</p></td></tr><tr><td style="height:14.65pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:14.65pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Laryngitis</p></td></tr><tr><td style="border-color:black; height:14.6pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Immune system disorders</p></td><td style="height:14.6pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:14.6pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Anaphylactic reaction</p></td></tr><tr><td rowspan="2" style="border-color:black; height:14.6pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Nervous system disorders</p></td><td style="height:14.6pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Common </em></p></td><td style="height:14.6pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Dysgeusia</p></td></tr><tr><td style="height:14.65pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:14.65pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Dizziness, paraesthesia</p></td></tr><tr><td rowspan="2" style="border-color:black; height:21.35pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Eye Disorders</p></td><td style="height:21.35pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Common</em></p></td><td style="height:21.35pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Eye pruritus</p></td></tr><tr><td style="height:13.9pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:13.9pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Conjunctivitis allergic</p></td></tr><tr><td rowspan="2" style="border-color:black; height:13.15pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Ear and labyrinth disorders</p></td><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Very common&nbsp; </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Ear pruritus</p></td></tr><tr><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Ear discomfort</p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Cardiac disorders</p></td><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Palpitations</p></td></tr><tr><td rowspan="4" style="border-color:black; height:13.2pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Respiratory, thoracic and mediastinal disorders&nbsp;</p></td><td style="height:13.2pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Very common&nbsp; </em></p></td><td style="height:13.2pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Throat irritation</p></td></tr><tr><td style="height:25.75pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Common&nbsp; </em></p></td><td style="height:25.75pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Asthma<sup>a</sup>, cough*, dysphonia, dyspnoea, oropharyngeal pain, pharyngeal oedema</p></td></tr><tr><td style="height:38.45pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:38.45pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Nasal congestion, nasal discomfort, nasal oedema, pharyngeal erythema, rhinorrhoea, sneezing, throat tightness, tonsillar hypertrophy</p></td></tr><tr><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Rare </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Laryngeal oedema, nasal obstruction, tracheal oedema</p></td></tr><tr><td rowspan="4" style="border-color:black; height:13.2pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Gastrointestinal disorders</p></td><td style="height:13.2pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Very common&nbsp; </em></p></td><td style="height:13.2pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Lip oedema, oedema mouth, oral pruritus&nbsp;</p></td></tr><tr><td style="height:63.7pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Common&nbsp; </em></p></td><td style="height:63.7pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:2.45pt; text-indent:0in">Abdominal pain, diarrhoea, dysphagia, dyspepsia, gastrooesophageal reflux disease, glossodynia, glossitis, lip pruritus, mouth ulceration, oral pain, tongue pruritus, nausea, oral discomfort, oral mucosal erythema, paraesthesia oral, stomatitis, tongue oedema, vomiting</p></td></tr><tr><td style="height:38.45pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:38.45pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Dry mouth, lip pain, lip ulceration, oesophageal irritation, oral mucosal blistering, salivary gland enlargement, salivary hypersecretion</p></td></tr><tr><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Rare </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Eosinophilic oesophagitis</p></td></tr><tr><td rowspan="3" style="border-color:black; height:13.15pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Skin and subcutaneous tissue disorders</p></td><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Common </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Pruritus, urticaria</p></td></tr><tr><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Erythema</p></td></tr><tr><td style="height:13.15pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Rare </em></p></td><td style="height:13.15pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Angioedema</p></td></tr><tr><td rowspan="2" style="border-color:black; height:13.2pt; vertical-align:top; width:126.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">General disorders and administration site conditions</p></td><td style="height:13.2pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Common </em></p></td><td style="height:13.2pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Chest discomfort, fatigue</p></td></tr><tr><td style="height:25.25pt; vertical-align:top; width:105.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em>Uncommon </em></p></td><td style="height:25.25pt; vertical-align:top; width:272.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Malaise, sensation of foreign body</p></td></tr></tbody></table><p style="margin-left:.55pt; margin-right:0in; text-indent:-.5pt">a) Isolated cases of severe acute worsening of asthma symptoms have been reported. Patients with known risk factors should not initiate treatment with ACARIZAX (see section 4.3 and 4.4).&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><em>&nbsp;</em></p><p>Description of selected adverse reactions</p><p style="margin-left:-.2pt; margin-right:10.7pt">If the patient experiences significant adverse reactions from the treatment, anti-allergic medication should be considered.</p><p style="margin-left:-.2pt; margin-right:10.7pt">Cases of serious systemic allergic reactions, including anaphylaxis have been reported post marketing. The medical supervision at first oral lyophilisate intake is therefore an important precaution (see section 4.2). In some cases the serious systemic allergic reaction has occurred at doses subsequent to the initial dose.&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">In case of acute worsening in asthma symptoms or severe systemic allergic reactions, angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, hypotension or feeling of fullness in the throat a physician should be contacted immediately. Hypertensive crisis has been reported following respiratory distress shortly after intake of ACARIZAX. In such cases treatment should be discontinued permanently or until otherwise advised by the physician.&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">*In clinical trials cough was observed with the same frequency for ACARIZAX and placebo.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p>Paediatric population</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX is not indicated in children &lt;12 years of age (see section 4.2). Only limited data from children 5-11 years of age are available and no data on treatment with ACARIZAX in children &lt;5 years of age exist. Reported adverse reactions in adolescents have been similar in frequency, type and severity as in adults.</p><p style="margin-left:.1pt; margin-right:0in; text-indent:0in"><strong><em>&nbsp;</em></strong></p><p style="margin-left:-.2pt; margin-right:10.7pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. To reports any side effect(s):</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><strong><em>&nbsp;</em></strong></p><p style="margin-left:36.05pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Saudi Arabia: </strong></p><table cellspacing="0" cellpadding="0" border="0" style="width:482.15pt"><tbody><tr><td style="height:67.4pt; vertical-align:top; width:1.65pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_29532"
   o:spid="_x0000_s1028" style='width:.7pt;height:11.6pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="9144,147320" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_812" o:spid="_x0000_s1029" style='position:absolute;
    width:0;height:147320;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="0,147320" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l,147320e" filled="f" strokeweight=".72pt">
    <v:path arrowok="t" textboxrect="0,0,0,147320"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><!--[if !vml]--><img width="2" height="17" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_3487/AC/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[endif]--><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:.7pt;height:11.6pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p></td><td style="height:67.4pt; vertical-align:top; width:480.55pt"><p style="margin-left:-59.15pt; margin-right:539.65pt; text-indent:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="0" style="width:478.9pt"><tbody><tr><td style="border-color:black; height:67.4pt; vertical-align:top; width:23.35pt"><p style="margin-left:5.35pt; margin-right:0in; text-indent:0in">&minus;</p></td><td style="border-color:black; height:67.4pt; vertical-align:top; width:455.55pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>The National Pharmacovigilance Center (NPC): </strong>&nbsp;</p><p style="margin-left:6.6pt; margin-right:0in; text-indent:-6.6pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Fax: +966-11-205-7662&nbsp;</p><p style="margin-left:6.6pt; margin-right:0in; text-indent:-6.6pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->SFDA Call Center: 19999&nbsp;</p><p style="margin-left:6.6pt; margin-right:0in; text-indent:-6.6pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p style="margin-left:6.6pt; margin-right:0in; text-indent:-6.6pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Website: https://ade.sfda.gov.sa/&nbsp;</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr></tbody></table><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><strong><em>&nbsp;</em></strong></p><p style="margin-left:36.05pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Other GCC countries: </strong></p><p style="margin-left:.85pt; margin-right:0in; text-indent:0in"><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_29531" o:spid="_x0000_s1026" style='width:.7pt;height:5.45pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9144,69215" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_804" o:spid="_x0000_s1027" style='position:absolute;
  width:0;height:69215;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="0,69215" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l,69215e" filled="f" strokeweight=".72pt">
  <v:path arrowok="t" textboxrect="0,0,0,69215"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_3487/AC/Temp/msohtmlclip1/01/clip_image002.gif" width="2" height="9" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:.7pt;height:5.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>&nbsp;</strong></p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Please contact the relevant competent authority.&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in"><strong><em>&nbsp;</em></strong></p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">In phase I studies adult patients with house dust mite allergy were exposed to doses up to 32 SQ-HDM. No data are available in adolescents regarding exposure to doses above the recommended daily dose of 12 SQHDM.&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">If doses higher than the recommended daily dose are taken, the risk of side effects increases, including the risk of systemic allergic reactions or severe local allergic reactions. In case of severe reactions such as angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, or feeling of fullness in the throat, immediate medical evaluation is needed. These reactions should be treated with relevant symptomatic medication.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">Pharmacotherapeutic group: Allergen extracts, house dust mite</p><p style="margin-left:-.2pt; margin-right:10.7pt">ATC code: V01AA03</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Mechanism of action</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX is allergy immunotherapy. Allergy immunotherapy with allergen products is the repeated administration of allergens to allergic individuals with the purpose of modifying the immunological response to the allergen.&nbsp;</p><p style="margin-left:-.2pt; margin-right:10.7pt">The immune system is the target for the pharmacodynamic effect of allergy immunotherapy, but the complete and exact mechanism of action regarding the clinical effect is not fully understood. Treatment with ACARIZAX has been demonstrated to induce an increase in house dust mite specific IgG<sub>4 </sub>and to induce a systemic antibody response that can compete with IgE in the binding of house dust mite allergens. This effect is observed already after 4 weeks of treatment.</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX works by addressing the cause of house dust mite respiratory allergic disease, and clinical effect during treatment has been demonstrated for both upper and lower airways. The underlying protection provided by ACARIZAX leads to improvement in disease control and improved quality of life demonstrated through symptom relief, reduced need for other medications and a reduced risk for exacerbation.&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Clinical efficacy in adults</p><p style="margin-left:-.2pt; margin-right:10.7pt">The efficacy of treatment with ACARIZAX 12 SQ-HDM in house dust mite respiratory allergic disease was investigated in two double-blind, randomised, placebo-controlled trials with different endpoints and in different patient populations. Two thirds of the trial subjects were sensitised to more allergens than just house dust mite. Being sensitised to house dust mite only or to house dust mite and one or more other allergens did not impact the trial results. Supportive evidence from an allergen exposure chamber trial as well as a trial conducted with lower doses is also presented.&nbsp;</p><p style="margin-left:-.2pt; margin-right:0in; text-indent:-.5pt"><strong><em>Allergic rhinitis </em></strong></p><p>The MERIT trial (MT-06)</p><p style="margin-left:36.05pt; margin-right:10.7pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The MERIT trial included 992 adults with moderate-to-severe house dust mite allergic rhinitis despite the use of rhinitis pharmacotherapy. Subjects were randomised to approximately 1 year of daily treatment with 12 SQ-HDM, 6 SQ-HDM or placebo and were given free access to standardised rhinitis pharmacotherapy. Subjects were seen by a specialist approximately every two months during the entire trial.&nbsp;</p><p style="margin-left:36.05pt; margin-right:10.7pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The primary endpoint was the average daily total combined rhinitis score (TCRS) evaluated during the last 8 weeks of treatment.&nbsp;</p><p style="margin-left:65.25pt; margin-right:10.7pt; text-indent:-11.2pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->The TCRS was the sum of the rhinitis symptoms score and the rhinitis medication score. The rhinitis symptoms score evaluated 4 nasal symptoms (runny nose, blocked nose, itching nose, sneezing) daily on a 0-3 scale (no, mild, moderate, severe symptoms), i.e. range of scale is 0-12. The rhinitis medication score was the sum of the score for nasal steroid intake (2 points per puff, max. 4 puffs/day) and oral antihistamine intake (4 points/tablet, max. 1 tablet/day), i.e. range: 0-12. Thus the TCRS range is: 0-24.&nbsp;</p><p style="margin-left:36.05pt; margin-right:10.7pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Additional pre-defined key secondary endpoints were the total combined rhinoconjunctivitis score and rhinoconjunctivitis quality of life (RQLQ).</p><p style="margin-left:36.05pt; margin-right:10.7pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Post-hoc analyses of the days with a rhinitis exacerbation were also conducted to further illustrate the clinical relevance of the results.&nbsp;</p><p style="margin-left:65.25pt; margin-right:10.7pt; text-indent:-11.2pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->A rhinitis exacerbation was defined as a day where the subject returned to the high level of symptoms required for trial inclusion: a rhinitis symptom score of at least 6 or at least 5 with one symptom rated severe.&nbsp;</p><p style="margin-left:65.25pt; margin-right:10.7pt; text-indent:-11.2pt">&nbsp;</p><p><img alt="" width="500" height="573" src="data:image/jpeg;base64,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" /></p><table cellspacing="0" cellpadding="0" border="0" align="left" style="width:194.15pt"><tbody><tr><td style="border-color:black; height:204.45pt; vertical-align:top; width:194.15pt"><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><strong>The MERIT trial: Development over time of the total combined rhinitis score&nbsp; </strong></p><p style="margin-left:0in; margin-right:12.1pt; text-indent:0in">TCRS: total combined rhinitis score (symptoms + medication score).&nbsp; The primary endpoint was the average daily TCRS during the last approximately 8 weeks of treatment (weeks ~44-52).</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Adjusted means of the average TCRS over time with error bars for the difference in adjusted means. Nonoverlapping intervals indicate a statistically significant difference.&nbsp;</p></td></tr></tbody></table><p style="margin-left:.05pt; margin-right:242.05pt; text-align:justify; text-indent:0in"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_916" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:247.8pt;height:283.2pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_3487/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><!--[if !vml]--></p><p style="margin-left:.05pt; margin-right:242.05pt; text-align:justify; text-indent:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="0" style="width:498.95pt"><tbody><tr><td style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>&nbsp;MERIT results </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:85.05pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in"><strong>12 SQ-HDM </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:90.6pt"><p style="margin-left:0in; margin-right:1.45pt; text-align:center; text-indent:0in"><strong>Placebo </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:135.9pt"><p style="margin-left:0in; margin-right:1.45pt; text-align:center; text-indent:0in"><strong>Treatment effect </strong></p></td><td style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:41.0pt"><p style="margin-left:1.45pt; margin-right:0in; text-align:center; text-indent:0in"><strong>&nbsp;</strong></p></td></tr><tr><td style="background-color:#f2f2f2; border-color:black; height:25.7pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Primary endpoint </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:35.4pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.3pt; text-align:center; text-indent:0in"><strong>Score </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:35.4pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>Score </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:65.3pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Absolute difference<sup> </sup></strong><sup>c</sup><strong> </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:70.6pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Relative difference<sup> </sup></strong><sup>d</sup><strong> </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>pvalue </strong></p></td></tr><tr><td colspan="5" style="height:13.25pt; vertical-align:top; width:322.1pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>Total combined rhinitis score </em></strong></p></td><td colspan="2" style="height:13.25pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:13.25pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS-MI<em><sup> </sup></em><sup>a</sup> (adjusted mean)<sup> </sup></p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">318</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">5.71</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">338</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">6.81</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">1.09<sup> </sup></p><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in">[0.35;1.84]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">-</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.004 </strong></p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup><em> </em>(adjusted mean)&nbsp;</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">5.53</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.05pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">6.76</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">1.22<sup> </sup></p><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in">[0.49;1.96]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">18%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.001 </strong></p></td></tr><tr><td style="border-color:black; height:13.2pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup> (median)</p></td><td style="height:13.2pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:13.2pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">5.88</p></td><td style="height:13.2pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:13.2pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">7.54</p></td><td style="height:13.2pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">1.66</p></td><td style="height:13.2pt; vertical-align:top; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">22%</p></td><td style="height:13.2pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>- </strong></p></td></tr><tr><td style="background-color:#f2f2f2; border-color:black; height:25.7pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Pre-defined key secondary endpoints </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:35.4pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.3pt; text-align:center; text-indent:0in"><strong>Score </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:35.4pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>Score </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:65.3pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Absolute difference</strong><sup> c</sup><strong> </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:70.6pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Relative difference<sup> </sup></strong><sup>d</sup><strong> </strong></p></td><td style="background-color:#f2f2f2; height:25.7pt; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>pvalue </strong></p></td></tr><tr><td colspan="5" style="height:13.2pt; vertical-align:top; width:322.1pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>Rhinitis symptoms score</em> </strong></p></td><td colspan="2" style="height:13.2pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:13.2pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup><em> </em>(adjusted mean)&nbsp;</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">2.76</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.05pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">3.30</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">0.54<sup> </sup></p><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in">[0.18;0.89]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">16%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.003 </strong></p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup> (median)</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:13.15pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">2.98</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:13.15pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">3.98</p></td><td style="height:13.15pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">1.00</p></td><td style="height:13.15pt; vertical-align:top; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">25%</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>- </strong></p></td></tr><tr><td colspan="5" style="height:13.15pt; vertical-align:top; width:322.1pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>Rhinitis medication score</em> </strong></p></td><td colspan="2" style="height:13.15pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup><em> </em>(adjusted mean)&nbsp;</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">2.22</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.05pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">2.83</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">0.60</p><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in">[0.08;1.13]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">21%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.024 </strong></p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup> (median)</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:13.15pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">2.83</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:13.15pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">4.00</p></td><td style="height:13.15pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">1.17</p></td><td style="height:13.15pt; vertical-align:top; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">29%</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>- </strong></p></td></tr><tr><td colspan="5" style="height:13.15pt; vertical-align:top; width:322.1pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>Total combined rhinoconjunctivitis score </em></strong></p></td><td colspan="2" style="height:13.15pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup><em> </em>(adjusted mean)&nbsp;</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">241</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">7.91</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.05pt; margin-right:0in; text-indent:0in">257</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">9.12</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">1.21<sup> </sup></p><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in">[0.13;2.28]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">13%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.029 </strong></p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup> (median)</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">241</p></td><td style="height:13.15pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">8.38</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">257</p></td><td style="height:13.15pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:1.3pt; text-align:center; text-indent:0in">10.05</p></td><td style="height:13.15pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">1.67</p></td><td style="height:13.15pt; vertical-align:top; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">17%</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>- </strong></p></td></tr><tr><td colspan="5" style="height:13.2pt; vertical-align:top; width:322.1pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>Rhinoconjunctivitis quality of life questionnaire (RQLQ(S)) score </em></strong></p></td><td colspan="2" style="height:13.2pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:13.2pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup><em> </em>(adjusted mean)&nbsp;</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">229</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">1.38</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:4.05pt; margin-right:0in; text-indent:0in">240</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">1.58</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.45pt; text-align:center; text-indent:0in">0.19 <sup>e </sup></p><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in">[0.02;0.37]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">12%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.031 </strong></p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup> b</sup><em> </em>(median)&nbsp;</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">229</p></td><td style="height:13.15pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:1.25pt; text-align:center; text-indent:0in">1.25</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">240</p></td><td style="height:13.15pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in">1.46</p></td><td style="height:13.15pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">0.21</p></td><td style="height:13.15pt; vertical-align:top; width:70.6pt"><p style="margin-left:0in; margin-right:1.4pt; text-align:center; text-indent:0in">14%</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:1.35pt; text-align:center; text-indent:0in"><strong>- </strong></p></td></tr><tr><td style="background-color:#d9d9d9; border-color:black; height:16.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>&nbsp;MERIT results </strong></p></td><td colspan="2" style="background-color:#d9d9d9; height:16.8pt; width:85.05pt"><p style="margin-left:0in; margin-right:.2pt; text-align:center; text-indent:0in"><strong>12 SQ-HDM </strong></p></td><td colspan="2" style="background-color:#d9d9d9; height:16.8pt; width:90.6pt"><p style="margin-left:0in; margin-right:.25pt; text-align:center; text-indent:0in"><strong>Placebo </strong></p></td><td colspan="2" style="background-color:#d9d9d9; height:16.8pt; width:135.9pt"><p style="margin-left:0in; margin-right:.25pt; text-align:center; text-indent:0in"><strong>Treatment effect </strong></p></td><td style="background-color:#d9d9d9; height:16.8pt; width:41.0pt"><p style="margin-left:2.65pt; margin-right:0in; text-align:center; text-indent:0in"><strong>&nbsp;</strong></p></td></tr><tr><td style="background-color:#f2f2f2; border-color:black; height:25.75pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Post-hoc endpoints </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:35.4pt"><p style="margin-left:0in; margin-right:.1pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:49.65pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Proportion </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:35.4pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:55.2pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Proportion </strong></p></td><td colspan="2" style="background-color:#f2f2f2; height:25.75pt; width:135.9pt"><p style="margin-left:0in; margin-right:.2pt; text-align:center; text-indent:0in"><strong>Odds ratio<sup> </sup></strong><sup>f</sup><strong> [95% CL] </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>pvalue </strong></p></td></tr><tr><td colspan="7" style="height:13.2pt; vertical-align:top; width:458.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>Probability of having a day with a rhinitis exacerbation </em></strong></p></td><td style="height:13.2pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS (estimate)<sup> b</sup><em> </em>&nbsp;</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:13.15pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center; text-indent:0in">5.33%</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:13.15pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:.2pt; text-align:center; text-indent:0in">11.14%</p></td><td colspan="2" style="height:13.15pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:.1pt; text-align:center; text-indent:0in">0.45 [0.28;0.72]<sup> </sup></p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.001 </strong></p></td></tr><tr><td colspan="7" style="height:13.2pt; vertical-align:top; width:458.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>Probability of having a day with a rhinitis exacerbation despite use of rhinitis pharmacotherapy </em></strong></p></td><td style="height:13.2pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS (estimate)<sup> b</sup><em> </em>&nbsp;</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">284</p></td><td style="height:13.15pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center; text-indent:0in">3.43%</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:4.1pt; margin-right:0in; text-indent:0in">298</p></td><td style="height:13.15pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center; text-indent:0in">6.50%</p></td><td colspan="2" style="height:13.15pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:.1pt; text-align:center; text-indent:0in">0.51 [0.32;0.81]<sup> </sup></p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.005 </strong></p></td></tr></tbody></table><p style="margin-left:5.2pt; margin-right:0in; text-indent:-.5pt">N: number of subjects in treatment group with data available for the analysis. CL: confidence limits</p><p style="margin-left:5.2pt; margin-right:13.4pt; text-indent:-.5pt"><!--[if !supportLists]--><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup><!--[endif]-->FAS-MI: full analysis set with multiple imputations. The analysis treats subjects who discontinued the trial before the efficacy assessment period as placebo subjects. For the primary analysis (FAS-MI) only the absolute difference was prespecified.</p><p style="margin-left:5.2pt; margin-right:13.4pt; text-indent:-.5pt"><!--[if !supportLists]--><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup><!--[endif]-->FAS: full analysis set. All available data used to its full extent, i.e. subjects who provided data during the efficacy assessment period. <sup>c</sup> Absolute difference: placebo minus 12 SQ-HDM, 95% confidence limits. <sup>d</sup> Relative difference to placebo: placebo minus 12 SQ-HDM divided by placebo.</p><p style="margin-left:9.4pt; margin-right:0in; text-indent:-4.7pt"><!--[if !supportLists]--><sup>e&nbsp; </sup><!--[endif]-->The difference between 12 SQ-HDM and placebo was primarily driven by differences in three domains: sleep problems, practical problems and nose symptoms.</p><p style="margin-left:9.4pt; margin-right:0in; text-indent:-4.7pt"><!--[if !supportLists]--><sup>f&nbsp; </sup><!--[endif]-->Odds ratio for having a rhinitis exacerbation: 12 SQ-HDM over placebo.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Supportive evidence &ndash; allergic rhinitis</p><p style="margin-left:-.2pt; margin-right:10.7pt">A randomised, double-blind, placebo-controlled phase II trial was conducted in an allergen exposure chamber in 124 adults with house dust mite allergic rhinitis. Before each allergen challenge, subjects were washed out of all allergy pharmacotherapy. At the end-of-trial allergen challenge after 24 weeks of treatment with 12 SQ-HDM, 6 SQ-HDM or placebo, the mean rhinitis symptoms score was 7.45 [6.57;8.33] in the placebo group and 3.83 [2.94;4.72] in the 12 SQ-HDM group, corresponding to an absolute difference of 3.62 and a relative difference of 49% (95% confidence interval [35%;60%], p&lt;0.001). The difference between 12 SQ-HDM and placebo was also statistically significant at 16 weeks (mean scores of 4.82 and</p><p style="margin-left:-.2pt; margin-right:10.7pt">6.90, difference of 2.08 corresponding to 30%, 95% CI [17%;42%], p&lt;0.001) and at 8 weeks (mean scores of</p><p style="margin-left:-.2pt; margin-right:10.7pt">5.34 and 6.71, difference of 1.37 corresponding to 20%, 95% CI [7%;33%], p=0.007).</p><p style="margin-left:-.2pt; margin-right:0in; text-indent:-.5pt"><strong><em>Allergic asthma </em></strong></p><p>The MITRA trial (MT-04)</p><p style="margin-left:36.5pt; margin-right:10.7pt">The MITRA trial included 834 adults with house dust mite allergic asthma not well-controlled by daily use of inhaled corticosteroid (ICS) corresponding to 400-1200 &micro;g budesonide. All subjects received 7-12 months&#39; treatment with ACARIZAX in addition to ICS and short-acting beta-agonist prior to ICS reduction. No titration phase to establish the lowest maintenance dose of ICS was conducted prior to randomisation. Efficacy was assessed by time to first moderate or severe asthma exacerbation under ICS reduction over the last 6 months of 13-18 months of treatment.</p><p style="margin-left:37.35pt; margin-right:14.1pt; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp; <!--[endif]-->The definition of a moderate asthma exacerbation was fulfilled if the subject experienced one or more of the 4 criteria below, and it led to change in treatment:&nbsp;</p><p style="margin-left:64.5pt; margin-right:5.9pt; text-indent:-8.5pt"><!--[if !supportLists]-->&sect; <!--[endif]--><u>Nocturnal awakening or increase in symptoms</u>: nocturnal awakening(s) due to asthma requiring short-acting &beta;<sub>2</sub> agonist (SABA) for two consecutive nights or increase of &ge;0.75 from baseline in daily symptom score on two consecutive days.&nbsp;</p><p style="margin-left:64.5pt; margin-right:5.9pt; text-indent:-8.5pt"><!--[if !supportLists]-->&sect; <!--[endif]--><u>Increased SABA use</u>: increase from baseline in occasions of SABA use on two consecutive days (minimum increase: 4 puffs/day).&nbsp;</p><p style="margin-left:64.5pt; margin-right:5.9pt; text-indent:-8.5pt"><!--[if !supportLists]-->&sect; <!--[endif]--><u>Deterioration in lung function</u>: &ge;20% decrease in PEF from baseline on at least two consecutive mornings/evenings or &ge;20% decrease in FEV1 from baseline. <u>Healthcare visit</u>:</p><p>&nbsp;</p><p>&nbsp;<p style="margin-left:65.7pt; margin-right:10.7pt">visit to the emergency room / trial site for asthma treatment not requiring systemic corticosteroids.</p></p><p style="margin-left:37.35pt; margin-right:14.1pt; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp; <!--[endif]-->A severe asthma exacerbation was defined as experiencing at least one of the two following:</p><p style="margin-left:64.5pt; margin-right:5.9pt; text-indent:-8.5pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Need for systemic corticosteroids for &ge;3 days</p><p style="margin-left:64.5pt; margin-right:5.9pt; text-indent:-8.5pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Emergency room visit requiring systemic corticosteroids or hospitalisation for &ge;12h.<strong><em> </em></strong></p><p style="margin-left:64.5pt; margin-right:5.9pt; text-indent:-8.5pt">&nbsp;</p><ul><li>.</li></ul><p>&nbsp;</p><p><img alt="" width="760" height="539" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="0" style="width:489.4pt"><tbody><tr><td style="height:233.2pt; vertical-align:top; width:329.35pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><!--[if gte vml 1]><v:shape id="Picture_x0020_2217"
   o:spid="_x0000_i1025" type="#_x0000_t75" style='width:327.6pt;height:232.2pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_3487/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><!--[if !vml]--><!--[endif]--></p></td><td style="height:233.2pt; vertical-align:top; width:160.05pt"><p style="margin-left:-386.05pt; margin-right:546.1pt; text-indent:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="0" style="width:158.35pt"><tbody><tr><td style="border-color:black; height:221.15pt; vertical-align:top; width:158.35pt"><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:4.85pt; text-indent:0in"><strong>The MITRA trial &ndash; illustration of primary efficacy data: Development over time of the risk for experiencing a moderate or severe asthma exacerbation during ICS reduction/withdrawal.&nbsp; </strong>On the graph time = 0 represents the time of the ICS reduction to 50%. After approximately 3 months, i.e. at time = 90 days, ICS was completely withdrawn for those subjects who had not exacerbated.</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr></tbody></table><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="0" style="width:488.75pt"><tbody><tr><td rowspan="2" style="background-color:#d9d9d9; border-color:black; height:25.75pt; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>MITRA results </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:25.75pt; width:85.0pt"><p style="margin-left:0in; margin-right:2.3pt; text-align:center; text-indent:0in"><strong>12 SQ-HDM </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:25.75pt; width:85.05pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>Placebo </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:25.75pt; width:141.75pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>Efficacy </strong></p><p style="margin-left:4.9pt; margin-right:0in; text-indent:0in"><strong>12 SQ-HDM over placebo </strong></p></td><td rowspan="2" style="background-color:#d9d9d9; border-color:black; height:25.75pt; width:44.0pt"><p style="margin-left:0in; margin-right:1.45pt; text-align:center; text-indent:0in"><strong>pvalue </strong></p></td></tr><tr><td style="background-color:#d9d9d9; height:38.45pt; width:28.3pt"><p style="margin-left:4.85pt; margin-right:0in; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:56.7pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in"><strong>n (%)<sup> </sup></strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:28.35pt"><p style="margin-left:4.85pt; margin-right:0in; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:56.7pt"><p style="margin-left:0in; margin-right:2.15pt; text-align:center; text-indent:0in"><strong>n (%)<sup> </sup></strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:70.85pt"><p style="margin-left:1.1pt; margin-right:.55pt; text-align:center; text-indent:0in"><strong>Hazard ratio </strong></p><p style="margin-left:0in; margin-right:2.15pt; text-align:center; text-indent:0in"><strong>[95% CL]&nbsp; </strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Risk reduction</strong><sup>a</sup><strong> </strong></p></td></tr><tr><td style="background-color:#f2f2f2; height:13.05pt; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Primary endpoint<sup> </sup></strong></p></td><td colspan="2" style="background-color:#f2f2f2; height:13.05pt; width:85.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td colspan="2" style="background-color:#f2f2f2; height:13.05pt; width:85.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td colspan="2" style="background-color:#f2f2f2; height:13.05pt; width:141.75pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="background-color:#f2f2f2; height:13.05pt; width:44.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.85pt; vertical-align:top; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Any exacerbation, moderate or severe (FAS-MI) <sup>b </sup></p></td><td style="height:25.85pt; width:28.3pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">282</p></td><td style="height:25.85pt; width:56.7pt"><p style="margin-left:2.4pt; margin-right:0in; text-indent:0in">59 (21%)</p></td><td style="height:25.85pt; width:28.35pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">277</p></td><td style="height:25.85pt; width:56.7pt"><p style="margin-left:2.45pt; margin-right:0in; text-indent:0in">83 (30%)</p></td><td style="height:25.85pt; vertical-align:top; width:70.85pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>0.69</strong></p><p style="margin-left:0in; margin-right:2.05pt; text-align:center; text-indent:0in">[0.50;0.96]</p></td><td style="height:25.85pt; width:70.9pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in">31%</p></td><td style="height:25.85pt; width:44.0pt"><p style="margin-left:0in; margin-right:2.1pt; text-align:center; text-indent:0in"><strong>0.027 </strong></p></td></tr><tr><td style="border-color:black; height:25.85pt; vertical-align:top; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Any exacerbation, moderate or severe (FAS) <sup>c </sup></p></td><td style="height:25.85pt; width:28.3pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">248</p></td><td style="height:25.85pt; width:56.7pt"><p style="margin-left:2.4pt; margin-right:0in; text-indent:0in">59 (24%)</p></td><td style="height:25.85pt; width:28.35pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">257</p></td><td style="height:25.85pt; width:56.7pt"><p style="margin-left:2.45pt; margin-right:0in; text-indent:0in">83 (32%)</p></td><td style="height:25.85pt; vertical-align:top; width:70.85pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>0.66</strong></p><p style="margin-left:0in; margin-right:2.05pt; text-align:center; text-indent:0in">[0.47;0.93]</p></td><td style="height:25.85pt; width:70.9pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in">34%</p></td><td style="height:25.85pt; width:44.0pt"><p style="margin-left:0in; margin-right:2.1pt; text-align:center; text-indent:0in"><strong>0.017 </strong></p></td></tr><tr><td rowspan="2" style="background-color:#d9d9d9; border-color:black; height:25.7pt; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>MITRA results </strong></p></td><td colspan="2" style="background-color:#d9d9d9; height:25.7pt; width:85.0pt"><p style="margin-left:0in; margin-right:2.3pt; text-align:center; text-indent:0in"><strong>12 SQ-HDM </strong></p></td><td colspan="2" style="background-color:#d9d9d9; height:25.7pt; width:85.05pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>Placebo </strong></p></td><td colspan="2" style="background-color:#d9d9d9; height:25.7pt; width:141.75pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>Efficacy </strong></p><p style="margin-left:4.9pt; margin-right:0in; text-indent:0in"><strong>12 SQ-HDM over placebo </strong></p></td><td rowspan="2" style="background-color:#d9d9d9; height:25.7pt; width:44.0pt"><p style="margin-left:0in; margin-right:1.45pt; text-align:center; text-indent:0in"><strong>pvalue </strong></p></td></tr><tr><td style="background-color:#d9d9d9; height:38.45pt; width:28.3pt"><p style="margin-left:4.85pt; margin-right:0in; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:56.7pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in"><strong>n (%)<sup> </sup></strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:28.35pt"><p style="margin-left:4.85pt; margin-right:0in; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:56.7pt"><p style="margin-left:0in; margin-right:2.15pt; text-align:center; text-indent:0in"><strong>n (%)<sup> </sup></strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:70.85pt"><p style="margin-left:1.1pt; margin-right:.55pt; text-align:center; text-indent:0in"><strong>Hazard ratio </strong></p><p style="margin-left:0in; margin-right:2.15pt; text-align:center; text-indent:0in"><strong>[95% CL]&nbsp; </strong></p></td><td style="background-color:#d9d9d9; height:38.45pt; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Risk reduction</strong><sup>a</sup><strong> </strong></p></td></tr><tr><td colspan="7" style="background-color:#f2f2f2; height:13.05pt; width:444.8pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Pre-defined analyses of components of the primary endpoint&nbsp; </strong></p></td><td style="background-color:#f2f2f2; height:13.05pt; width:44.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.85pt; vertical-align:top; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Nocturnal awakening or increase in symptoms <sup>c </sup></p></td><td style="height:25.85pt; width:28.3pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">248</p></td><td style="height:25.85pt; width:56.7pt"><p style="margin-left:2.4pt; margin-right:0in; text-indent:0in">39 (16%)</p></td><td style="height:25.85pt; width:28.35pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">257</p></td><td style="height:25.85pt; width:56.7pt"><p style="margin-left:2.45pt; margin-right:0in; text-indent:0in">57 (22%)</p></td><td style="height:25.85pt; vertical-align:top; width:70.85pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>0.64</strong></p><p style="margin-left:0in; margin-right:2.05pt; text-align:center; text-indent:0in">[0.42;0.96]</p></td><td style="height:25.85pt; width:70.9pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in">36%</p></td><td style="height:25.85pt; width:44.0pt"><p style="margin-left:0in; margin-right:2.1pt; text-align:center; text-indent:0in"><strong>0.031 </strong></p></td></tr><tr><td style="border-color:black; height:25.8pt; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Increased SABA use <sup>c </sup></p></td><td style="height:25.8pt; width:28.3pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">248</p></td><td style="height:25.8pt; width:56.7pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in">18 (7%)</p></td><td style="height:25.8pt; width:28.35pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">257</p></td><td style="height:25.8pt; width:56.7pt"><p style="margin-left:2.45pt; margin-right:0in; text-indent:0in">32 (12%)</p></td><td style="height:25.8pt; vertical-align:top; width:70.85pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>0.52</strong></p><p style="margin-left:0in; margin-right:2.05pt; text-align:center; text-indent:0in">[0.29;0.94]</p></td><td style="height:25.8pt; width:70.9pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in">48%</p></td><td style="height:25.8pt; width:44.0pt"><p style="margin-left:0in; margin-right:2.1pt; text-align:center; text-indent:0in"><strong>0.029 </strong></p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-align:justify; text-indent:0in">Deterioration in lung function<sup> c </sup></p></td><td style="height:25.8pt; width:28.3pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">248</p></td><td style="height:25.8pt; width:56.7pt"><p style="margin-left:2.4pt; margin-right:0in; text-indent:0in">30 (12%)</p></td><td style="height:25.8pt; width:28.35pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">257</p></td><td style="height:25.8pt; width:56.7pt"><p style="margin-left:2.45pt; margin-right:0in; text-indent:0in">45 (18%)</p></td><td style="height:25.8pt; vertical-align:top; width:70.85pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in"><strong>0.58</strong></p><p style="margin-left:0in; margin-right:2.05pt; text-align:center; text-indent:0in">[0.36;0.93]</p></td><td style="height:25.8pt; width:70.9pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in">42%</p></td><td style="height:25.8pt; width:44.0pt"><p style="margin-left:0in; margin-right:2.1pt; text-align:center; text-indent:0in"><strong>0.022 </strong></p></td></tr><tr><td style="border-color:black; height:25.8pt; width:132.95pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">Severe exacerbation <sup>c </sup></p></td><td style="height:25.8pt; width:28.3pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">248</p></td><td style="height:25.8pt; width:56.7pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in">10 (4%)</p></td><td style="height:25.8pt; width:28.35pt"><p style="margin-left:.6pt; margin-right:0in; text-indent:0in">257</p></td><td style="height:25.8pt; width:56.7pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in">18 (7%)</p></td><td style="height:25.8pt; vertical-align:top; width:70.85pt"><p style="margin-left:0in; margin-right:2.25pt; text-align:center; text-indent:0in">0.49</p><p style="margin-left:0in; margin-right:2.05pt; text-align:center; text-indent:0in">[0.23;1.08]</p></td><td style="height:25.8pt; width:70.9pt"><p style="margin-left:0in; margin-right:2.2pt; text-align:center; text-indent:0in">51%</p></td><td style="height:25.8pt; width:44.0pt"><p style="margin-left:0in; margin-right:2.1pt; text-align:center; text-indent:0in">0.076</p></td></tr></tbody></table><p style="margin-left:.55pt; margin-right:4.6pt; text-indent:-.5pt">N: number of subjects in treatment group with data available for the analysis. n (%): number and percentage of subjects in treatment group meeting criterion. CL: confidence limits <sup>a </sup>Estimated by hazard ratio <sup>b</sup> FAS-MI: full analysis set with multiple imputations. The analysis treats subjects who discontinued the trial before the efficacy assessment period as placebo subjects.</p><p style="margin-left:.55pt; margin-right:0in; text-indent:-.5pt"><sup>c</sup> FAS: full analysis set. All available data used to its full extent, i.e. including all subjects who provided data during the efficacy assessment period.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><strong><em>&nbsp;</em></strong></p><p style="margin-left:-.2pt">Post-hoc analyses of the asthma symptoms and symptomatic medication use in the last 4 weeks of the treatment period prior to reduction of inhaled corticosteroids were also conducted to investigate the effect of ACARIZAX as add-on to inhaled corticosteroid. The analyses looked at asthma daytime and nocturnal symptom scores, nocturnal awakenings, and SABA intake. The post-hoc analyses showed numerical differences consistently in favour of 12 SQ-HDM over placebo for all parameters investigated during the last 4 weeks prior to inhaled corticosteroid reduction. The differences were only statistically significant for the asthma daytime symptom score (p=0.0450) and the odds for no nocturnal awakenings (p=0.0409).<strong><em> </em></strong></p><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>&nbsp;</em></strong></p><p>Supportive evidence &ndash; allergic asthma</p><p style="margin-left:-.2pt">In a double-blind, randomised, placebo-controlled phase II trial, 604 subjects &ge;14 years old with house dust mite allergic asthma controlled by inhaled corticosteroids (100-800&micro;g budesonide) and a clinical history of house dust mite allergic rhinitis were randomised&nbsp; to approximately 1 year of treatment with 1, 3 or 6 SQHDM or placebo. At the 4-week end-of-trial efficacy evaluation period, the mean change from baseline in the daily ICS dose was 207.6 &micro;g budesonide in the 6 SQ-HDM group and 126.3 &micro;g in the placebo group corresponding to an absolute difference of 81 &micro;g budesonide per day (95% confidence interval [27;136], p= 0.004. Relative mean and median ICS reductions from baseline were 42% and 50% for 6 SQ-HDM and 15% and 25% for placebo. In a post-hoc analysis of a subgroup (N=108) of subjects with lower asthma control and ICS &ge;400 &micro;g budesonide, the mean change from baseline in the daily ICS dose was 384.4 &micro;g budesonide in the 6 SQ-HDM group and 57.8 &micro;g in the placebo group corresponding to an absolute difference between 6 SQ-HDM and placebo of 327 &micro;g budesonide per day (95% CI [182;471], p&lt;0.0001, post-hoc analysis).&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:-.15pt; margin-right:348.6pt; text-indent:-.5pt"><u>Paediatric population</u> <strong><em>Allergic rhinitis: </em></strong></p><p>Children 5-11 years of age</p><p style="margin-left:-.2pt; margin-right:10.7pt">Clinical experience in treatment of allergic rhinitis with ACARIZAX in children &lt;12 years of age has not been established.&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><em>&nbsp;</em></p><p>Adolescents 12-17 years of age</p><p style="margin-left:-.2pt; margin-right:0in">The efficacy of treatment with ACARIZAX 12 SQ-HDM in house dust mite allergic rhinitis in adolescents was investigated in two double-blind, randomised, placebo-controlled trials (P001 and TO-203-3-2). In these studies a proportion of the subjects were adolescents.</p><p style="margin-left:.25in; margin-right:5.35pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The P001 trial included 189 adolescents (of 1482 subjects randomised in total) with moderate-to-severe house dust mite allergic rhinitis/rhinoconjunctivitis with or without asthma. Subjects were randomised to approximately 1 year of daily treatment with 12 SQ-HDM or placebo and were given free access to standardised rhinitis pharmacotherapy.&nbsp;</p><p style="margin-left:18.5pt; margin-right:10.7pt">The primary endpoint was the average daily total combined rhinitis score (TCRS) evaluated during the last 8 weeks of treatment.&nbsp;</p><p style="margin-left:18.45pt; margin-right:10.7pt">After 1 year of treatment with 12 SQ-HDM, an absolute difference in medians of 1.0 (95% confidence interval [0.1; 2.0]) and a relative difference of 22% (p=0.024) compared to placebo was found in the adolescent group.</p><p style="margin-left:.25in; margin-right:5.35pt; text-indent:-.25in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The TO-203-3-2 trial included 278 adolescents (of 851 subjects randomised in total) with moderate-tosevere persistent house dust mite allergic rhinitis. Subjects were randomised to approximately 1 year of daily treatment with 12 SQ-HDM, 6 SQ-HDM, or placebo and were given free access to standardised rhinitis pharmacotherapy.&nbsp;</p><p style="margin-left:18.45pt; margin-right:10.7pt">The primary endpoint was the average daily TCRS evaluated during the last 8 weeks of treatment.</p><p style="margin-left:18.4pt">At the end-of-trial after 1 year of treatment with 12 SQ-HDM, an absolute difference in means of 1.0 (95% confidence interval [0.1; 1.9], p=0.037) and a relative difference of 20% compared to placebo was found in the adolescent group.</p><table cellspacing="0" cellpadding="0" border="0" style="width:498.95pt"><tbody><tr><td style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Adolescent subgroups </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:85.05pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in"><strong>12 SQ-HDM </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:90.6pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in"><strong>Placebo </strong></p></td><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:135.9pt"><p style="margin-left:0in; margin-right:.8pt; text-align:center; text-indent:0in"><strong>Treatment effect </strong></p></td><td style="background-color:#d9d9d9; border-color:black; height:16.85pt; width:41.0pt"><p style="margin-left:2.15pt; margin-right:0in; text-align:center; text-indent:0in"><strong>&nbsp;</strong></p></td></tr><tr><td style="background-color:#f2f2f2; border-color:black; height:25.75pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>Primary endpoint: TCRS </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:35.4pt"><p style="margin-left:0in; margin-right:.6pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:49.65pt"><p style="margin-left:0in; margin-right:.6pt; text-align:center; text-indent:0in"><strong>Score </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:35.4pt"><p style="margin-left:0in; margin-right:.65pt; text-align:center; text-indent:0in"><strong>N </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:55.2pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in"><strong>Score </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:65.3pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Absolute difference<sup> </sup>&nbsp;</strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:70.6pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>Relative difference<sup> </sup></strong><sup>d</sup><strong> </strong></p></td><td style="background-color:#f2f2f2; height:25.75pt; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in"><strong>pvalue </strong></p></td></tr><tr><td style="height:13.2pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>P001 </em></strong></p></td><td colspan="2" style="height:13.2pt; vertical-align:top; width:85.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td colspan="2" style="height:13.2pt; vertical-align:top; width:90.6pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td colspan="2" style="height:13.2pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:13.2pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup>&nbsp; </sup>(adjusted mean)</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:0in; margin-right:.6pt; text-align:center; text-indent:0in">76</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:.6pt; text-align:center; text-indent:0in">3.6</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">84</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">4.8</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:0in; text-align:center; text-indent:0in">1.2 <sup>a </sup>[0.1;2.3]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in">25%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.4pt; margin-right:0in; text-indent:0in"><strong>&lt;0.05 </strong></p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS (median)<sup> </sup></p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:0in; margin-right:.65pt; text-align:center; text-indent:0in">76</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:.6pt; text-align:center; text-indent:0in">3.3</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">84</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">4.3</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in">1.0 <sup>b </sup></p><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">[0.1;2.0]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in">22%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.024 </strong></p></td></tr><tr><td style="height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong><em>TO-203-3-2</em> </strong></p></td><td colspan="2" style="height:13.15pt; vertical-align:top; width:85.05pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td colspan="2" style="height:13.15pt; vertical-align:top; width:90.6pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td colspan="2" style="height:13.15pt; vertical-align:top; width:135.9pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<em> </em>(adjusted mean)&nbsp;</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:0in; margin-right:.65pt; text-align:center; text-indent:0in">99</p></td><td style="height:25.8pt; width:49.65pt"><p style="margin-left:0in; margin-right:.65pt; text-align:center; text-indent:0in">4.1</p></td><td style="height:25.8pt; width:35.4pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">92</p></td><td style="height:25.8pt; width:55.2pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in">5.1</p></td><td style="height:25.8pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">1.0 <sup>c</sup></p><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">[0.1;1.9]</p></td><td style="height:25.8pt; width:70.6pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in">20%</p></td><td style="height:25.8pt; width:41.0pt"><p style="margin-left:2.8pt; margin-right:0in; text-indent:0in"><strong>0.037 </strong></p></td></tr><tr><td style="border-color:black; height:13.15pt; vertical-align:top; width:146.45pt"><p style="margin-left:0in; margin-right:0in; text-indent:0in">FAS<sup>&nbsp; </sup>(median)</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:0in; margin-right:.65pt; text-align:center; text-indent:0in">99</p></td><td style="height:13.15pt; vertical-align:top; width:49.65pt"><p style="margin-left:0in; margin-right:.6pt; text-align:center; text-indent:0in">4.2</p></td><td style="height:13.15pt; vertical-align:top; width:35.4pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">92</p></td><td style="height:13.15pt; vertical-align:top; width:55.2pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in">5.2</p></td><td style="height:13.15pt; vertical-align:top; width:65.3pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in">1.0</p></td><td style="height:13.15pt; vertical-align:top; width:70.6pt"><p style="margin-left:0in; margin-right:.75pt; text-align:center; text-indent:0in">19%</p></td><td style="height:13.15pt; vertical-align:top; width:41.0pt"><p style="margin-left:0in; margin-right:.7pt; text-align:center; text-indent:0in"><strong>- </strong></p></td></tr></tbody></table><p style="margin-left:5.2pt; margin-right:323.1pt; text-indent:-.5pt">TCRS: total combined rhinitis score <sup>a</sup>: ANCOVA</p><p style="margin-left:5.2pt; margin-right:93.05pt; text-indent:-.5pt"><sup>b</sup>: Hodges-Lehmann estimate with 95% confidence intervals (primary analysis in the P001 trial) <sup>c</sup>: Linear mixed-effects model (primary analysis in the TO-203-3-2 trial) <sup>d</sup>: Relative difference to placebo: placebo minus 12 SQ-HDM divided by placebo<strong> </strong></p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in"><strong><em>&nbsp;</em></strong></p><p style="margin-left:-.2pt; margin-right:0in; text-indent:-.5pt"><strong><em>Allergic asthma: </em></strong></p><p>Paediatric population 5-17 years of age</p><p style="margin-left:-.2pt; margin-right:10.7pt">Clinical experience in treatment of allergic asthma with ACARIZAX in children &lt;18 years of age has not been established.&nbsp;</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Elderly population</p><p style="margin-left:-.2pt; margin-right:10.7pt">ACARIZAX is not indicated in patients &gt;65 years of age (see section 4.2). Limited safety and tolerability data exist for elderly patients &gt;65 years of age.</p><p style="margin-left:.05pt; margin-right:0in; text-indent:0in">&nbsp;</p><p>Long-term treatment&nbsp;</p><p style="margin-left:-.2pt; margin-right:0in">International treatment guidelines refer to a treatment period of 3 years for allergy immunotherapy to achieve disease modification. Efficacy data is available for 18 months of treatment with ACARIZAX from the MITRA trial. Long-term efficacy has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt">No clinical studies investigating the pharmacokinetic profile and metabolism of ACARIZAX have been conducted. The effect of allergy immunotherapy is mediated through immunological mechanisms, and there is limited information available on the pharmacokinetic properties.&nbsp;</p><p style="margin-left:-.2pt; margin-right:0in">The active molecules of an allergen extract are composed primarily of proteins. For sublingually administered allergy immunotherapy products, studies have shown that no passive absorption of the allergen through the oral mucosa occurs. Evidence points towards the allergen being taken up through the oral mucosa by dendritic cells, in particular Langerhans cells. Allergen which is not absorbed in this manner is expected to be hydrolysed to amino acids and small polypeptides in the lumen of the gastrointestinal tract. There is no evidence to suggest that the allergens present in ACARIZAX are absorbed into the vascular system after sublingual administration to any significant extent.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">Conventional studies of general toxicology and toxicity to reproduction in mice have revealed no special hazards to humans.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">Gelatine (fish source)</p><p style="margin-left:-.2pt; margin-right:10.7pt">Mannitol</p><p style="margin-left:-.2pt; margin-right:10.7pt">Sodium hydroxide (for pH adjustment)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">Aluminium/aluminium blister cards in outer carton. Each blister card contains 10 oral lyophilisates.</p><p style="margin-left:-.2pt; margin-right:10.7pt">Pack sizes: 30.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-.2pt; margin-right:10.7pt">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ALK-Abelló A/S 
Bøge Alle 6-8 
2970 Hørsholm 
Denmark 
Tel: +45 45 74 75 76 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>